Compound ID | 8
Suvratoxumab, MEDI4893, LC-10
Class: Antibody
| Spectrum of activity: | Gram-positive |
| Details of activity: | MEDI4893, also known as LC-10, in addition to an antibiotic treatment regimen against S. aureus. SSTI provides a benefit at multiple stages of the infection and healing process. |
| Combined with other compounds: | Yes |
| Institute where first reported: | Medimmune, USA |
| Year first mentioned: | 2012 |
| Highest developmental phase: | Phase 3 (NCT05331885) |
| Development status: | Active |
| External links: | |
| Guide to Pharmacology: | suvratoxumab |
| Main Source: | https://clinicaltrials.gov/ct2/show/NCT02296320?term=MEDI4893&rank=1 |
| Citation: | http://aac.asm.org/content/59/1/299.full |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us.
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.